Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06412562 on Value-based Decision-making in Healthy Individuals
NCT03181841Phase 1Completed
- Sponsor
- University of Zurich
- Start
- May 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of razpipadon in schizophrenia, substance-related disorders, major depressive disorder (MDD) and 1 more (4 arms), sponsored by University of Zurich. Primary endpoints: Change from baseline in a delay discounting task, Change from baseline in a risk discounting task and 4 more. Started May 2017; status: completed.
02
Drugs
razpipadon
03
Conditions
schizophreniasubstance-related disordersmajor depressive disorder (MDD)Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03181841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03181841.